GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GeneThera Inc (OTCPK:GTHR) » Definitions » Net Income

GeneThera (GeneThera) Net Income : $-0.68 Mil (TTM As of Sep. 2022)


View and export this data going back to 2000. Start your Free Trial

What is GeneThera Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. GeneThera's Net Income for the three months ended in Sep. 2022 was $-0.13 Mil. Its Net Income for the trailing twelve months (TTM) ended in Sep. 2022 was $-0.68 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. GeneThera's Earnings per Share (Diluted) for the three months ended in Sep. 2022 was $-0.00.


GeneThera Net Income Historical Data

The historical data trend for GeneThera's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GeneThera Net Income Chart

GeneThera Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Net Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.76 -3.40 -0.52 -0.77 -1.01

GeneThera Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.24 -0.28 -0.13 -0.15 -0.13

GeneThera Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

GeneThera's Net Income for the fiscal year that ended in Dec. 2021 is calculated as

Net Income(A: Dec. 2021 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-1.011+0+0+0
=-1.01

GeneThera's Net Income for the quarter that ended in Sep. 2022 is calculated as

Net Income(Q: Sep. 2022 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-0.126+0+0+0
=-0.13

Net Income for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.68 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GeneThera  (OTCPK:GTHR) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

GeneThera's Earnings per Share (Diluted) (EPS) for the quarter that ended in Sep. 2022 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


GeneThera Net Income Related Terms

Thank you for viewing the detailed overview of GeneThera's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


GeneThera (GeneThera) Business Description

Traded in Other Exchanges
N/A
Address
3051 W 105th Avenue, Suite 350251, Westminster, CO, USA, 80035
GeneThera Inc is a biotechnology company using its proprietary molecular sciences and technologies dedicated to eradicating diseases such as COVID-19, Paratuberculosis, Mad Cow Disease, Chronic Wasting Disease, and E.coli and Salmonella infections. It focuses on developing novel molecular diagnostic tests, therapeutics, and vaccines through its proprietary robotic technologies. Its Molecular Robotic/AI Platform and Therapeutic strategy (MORAPAT) is designed to prevent the spread of disease from animals and at the same time, allow better control of zoonotic infectious agents. The company has also developed a molecular system for the detection of Mycobacterium Avian Paratuberculosis in the milk of infected dairy cows.
Executives
Avel Kolesnikov director 11353 COLONY CIRCLE, BROOMFIELD CO 80020
Mcnece Elmer Roy Jr 10 percent owner 632 CANTRILL DRIVE, DAVIS CA 95616
Fidra Holdings Ltd 10 percent owner CABLE BEACH COURT, ONE WEST BAY STREET, NASSAU BAHAMAS C5 00000
Steven Michael Grubner director, officer: Chief Financial Officer 728 S. PRAIRIE AVENUE, BARRINGTON IL 60010
Antonio Milici director, 10 percent owner, officer: Chief Executive Officer 3930 YOUNGFIELD, WHEAT RIDGE CO 80033
Tannya L Irizarry director, 10 percent owner, officer: Chief Administative Officer 11880 ANTLER TR, LITTLETON CO 80127

GeneThera (GeneThera) Headlines

No Headlines